Outpatient antidepressant utilization in a Dutch sick fund

American Journal of Managed Care

Volumn 4, Issue 8, 1998, Pages 1150-1160

  Gregor, Karl J ^d   Hylan, Timothy R ^a   Van Dijk, Paul C M ^f   Sier, Frans ^f   Quik, Ralph ^b   Kleintjens, Harry Th ^c   Kloppenburg, Tycho ^e   Young, Christopher H ^d  

^a ELI LILLY AND COMPANY   (United States)

^b Eli Lilly Nederland   (Netherlands)

^c Eli Lilly International Corporation   (United Kingdom)

^d PCS Health Systems Incorporated   (United States)

^e RCAB Stichting   (Netherlands)

^f ZAO Zorgverzekeringen   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; FLUOXETINE; FLUVOXAMINE; HYPNOTIC SEDATIVE AGENT; PAROXETINE;

ADULT; AGED; ARTICLE; DEPRESSION; DRUG USE; FEMALE; FINANCIAL MANAGEMENT; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL;

AMBULATORY CARE; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; DRUG UTILIZATION REVIEW; HUMANS; HYPNOTICS AND SEDATIVES; INSURANCE, PHARMACEUTICAL SERVICES; LONGITUDINAL STUDIES; NATIONAL HEALTH PROGRAMS; NETHERLANDS; PRESCRIPTIONS, DRUG; QUALITY ASSURANCE, HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 0031783401     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Rosholm JU, Hallas J, Gram L. Outpatient utilization of antidepressants: A prescription drug database analysis. J Affect Disord 1993;27:21-28.
2. Donoghue JM, Tylee A. The treatment of depression: Prescribing patterns of antidepressants in primary care in the UK. Br J Psychiatry 1996;168:164-168.
3. Soutre E, Martin P, Lozet H, Monteban H. Quality of life in depressed patients: Comparison of fluoxetine and major tricyclic antidepressants. Int Clin Psychopharmacol 1996; 11:45-52.
4. Arpino C, Da Cas R, Donini G, et al. Use and misuse of antidepressant drugs in a random sample of the population of Rome, Italy. Acta Psychiatr Scand 1995;92:7-9.
5. Katon W, Von Korff M, Lin E, Bush T, Ormel J. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992;30:67-76.
6. Simon GE, Von Korff M, Wagner EH, Barlow W. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993;15:399-408.
7. de Waal M, Stolk J, van Marwijk HW, Springer MP. Voorschrijven van antidepressiva in de huisartspraktijk [Prescription of antidepressants in family practice]. Ned Tijdschr Geneeskd 1996;140-143:2131-2134.
8. Johnson D. Noncompliance with antidepressant therapy - an underestimated problem. Intern Med 1986;11:14-17.
9. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33:67-74.
10. Simon GE, Von Korff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: Effectiveness and cost of fluoxetine vs. tricyclic antidepressants. JAMA 1996; 275:1897-1902.
11. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization. Clin Ther 1994;16:715-730.
12. Sclar DA, Skaer TL, Robison LM, et al. Economic outcomes with antidepressant pharmacotherapy: A retrospective intent-to-treat analysis. J Clin Psychiatry. In press.
13. Katzelnick DJ, Kobak KA, Jefferson JW, Greist JH, Henk HJ. Prescribing patterns of antidepressant medications for depression in an HMO. Formulary 1996;31:374-388.
14. Skaer TL, Sclar DA, Robison LM, et al. Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Current Therapeutic Research 1995;56:556-567.
15. Thompson D, Buesching D, Gregor KJ, Oster G. Patterns of antidepressant use and their relation to costs of care. Am J Man Care 1996;2:1239-1246.
16. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization. J Int Med Res 1995;23:395-412.
17. Sclar DA, Skaer TL, Robison LM, et al. Evidence-based algorithm for antidepressant pharmacotherapy. JAMA: SE Asia Edition 1997;13(suppl. 1):33-40.
18. Gregor KJ, Overhage JM, Coon SJ, McDonald RC. Selective serotonin reuptake inhibitor dose titration in a naturalistic setting. Clin Ther 1994;16:306-315.
19. Rascati K. Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Ther 1995;17:786-790.
20. Gregor KJ, Riley JA, Downing DK. Concomitant use of anxiolytic and hypnotics with selective serotonin reuptake inhibitors. Clin Ther 1996;18:521-527.
21. Hylan TR, Neslusan CA, Baldridge RM, Meneades L, Crown WH. SSRI antidepressant selection and anxiolytic and sedative-hypnotic use. J Clin Outcomes Manage 1997;4:16-22.
22. Pathiyal A, Hylan TR, Jones JK, et al. SSRI and anxiolytic and sedative-hypnotic prescribing in a general practitioner setting in the Netherlands: A multivariate analysis. Clin Ther 1997;19:798-810.
23. Simon G, Wagner E, Von Korff M. Cost-effectiveness comparisons using "real world" randomized trials: the case of the new antidepressant drugs. J Clin Epidemiol 1995; 48:363-373.
24. de Vos CM. The 1996 pricing and reimbursement policy in the Netherlands. Pharmacoeconomics 1996;10(suppl. 2):75-80.
25. Kasper S, Fuger J, Moller HJ. Comparative efficacy of antidepressants. Drugs 1992;43(suppl. 2):11-22.
26. Katon W, Robinson P, Von Korff M, et al. A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry 1996;53:924-932.
27. Sturm R, Wells KB. How can care for depression become more cost-effective? JAMA 1995;273:51-58.
28. Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761-768.
29. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcomes for maintenance in recurrent depression. Arch Gen Psychiatry 1992;49:769-773.
30. Frank E, Perel JM, Mallinger AG, Thase ME, Kupfer DJ. Relationship of pharmacologic compliance to long-term prophylaxis in recurrent depression. Psychopharmacol Bull 1992;28:231-235.
31. Maj M, Veltro F, Pirozzi R, Lobrace S, Magliano L. Pattern of recurrence of illness after recovery from an episode of major depression: A prospective study. Am J Psychiatry 1992;149:795-800.
32. Altamura AC, Percudani M. The use of antidepressants for long-term treatment of recurrent depression: Rationale, current methodologies, and future direction. J Clin Psychiatry 1993;54(8 suppl):29-38.
33. Van Marwijk HWJ, Grundmeijer HGLM, Brueren MM, et al. NHG Standaard Depressie. Huisarts in Wetenschap 1994;37:482-490.
34. van der Kuy A. Farmacotherapeutisch Kompas 1997. Amsterdam, The Netherlands: Ziekenfondsraad; 1997.
35. Clinical Practice Guideline Number 5. Depression in Primary Care, 2: Treatment of Major Depression. Rockville, MD: US Dept of Health and Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0551.
36. Streator SE, Moss JT. Non-approved usage identification of off-label antidepressant use and costs in a network model HMO. Drug Benefit Trends 1997;9:48-56.
37. Rasmussen SA, Eisen JL, Pato MT. Current issues in the pharmacologic management of obsessive compulsive disorder. J Clin Psychiatry 1993;54(6 suppl):4-9.
38. Ormel J, van den Brink W, van den Meer K, Jenner J, Giel R. Prevalentie, signalering en beloop van depressie in de huisartsenpraktijk [Prevalence, indication and course of depression in family practice]. Ned Tijdschr Geneeskd 1994;3:123-126.
39. Van den Brink W, Ormel J. Depressie in de huisartsenpraktijk. Consequenties voor onderwijs, onderzoek en beleid. Tijdschrift voor Psychiatrie 1993;35:95-109.
40. de Jonghe F. Medicamenteuze behandeling van depressies. Tijdschrift voor huisartsgeneedskunde 1995;3:153-158.
41. Benkert O, Szegedi A, Wetzel H. Minimum effective dose for antidepressants - an obligatory requirement for antidepressant drug evaluation? Int Clin Psychopharmacol 1996;11:177-185.
42. Frost L, Lal S. Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors [letter]. Am J Psychiatry 1995;152:810.